Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.98 USD
-0.02 (-1.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.97 -0.01 (-0.51%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENTX 1.98 -0.02(-1.00%)
Will ENTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTX
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Other News for ENTX
Biotech Alert: Searches spiking for these stocks today
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Biotech Alert: Searches spiking for these stocks today
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research